Eliem Therapeutics Reports Second Quarter Financial Results
Eliem Therapeutics, Inc (ELYM)
Company Research
Source: GlobeNewswire
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents of approximately $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for budoprutug SEATTLE and CAMBRIDGE, United Kingdom, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem” or the “Company”), today reported financial results for the quarter ended June 30, 2024 and provided a business update. “Following the close of the Tenet Medicines acquisition and the concurrent financing, we believe Eliem is well-positioned as we transition to becoming a leading development stage immunology company,” said Dr. Aoife Brennan, CEO of Eliem. “Our lead product candidate, budoprutug, is an ant
Show less
Read more
Impact Snapshot
Event Time:
ELYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELYM alerts
High impacting Eliem Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
ELYM
News
- Eliem Therapeutics rebrands as Climb Bio with new name and logo [Seeking Alpha]Seeking Alpha
- Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.GlobeNewswire
- Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m [Yahoo! Finance]Yahoo! Finance
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitGlobeNewswire
- Eliem Therapeutics Announces Additions to its Leadership TeamGlobeNewswire
ELYM
Sec Filings
- 10/2/24 - Form 8-K
- 9/20/24 - Form 4
- 8/27/24 - Form 8-K
- ELYM's page on the SEC website